BIOMARIN PHARMACEUTICAL INC — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 78/100
What the filing says
On April 27, 2026, BioMarin Pharmaceutical Inc. completed its merger with Amicus Therapeutics, Inc., with Amicus becoming a wholly owned subsidiary of BioMarin. The Amicus 2025 Equity Incentive Plan was assumed by BioMarin effective April 27, 2026, covering 4,355,297 shares of common stock available for issuance under the assumed plan. BioMarin's own 2017 Equity Incentive Plan remains in effect with a total share reserve of 72,030,015 shares.
Why this rating
Major acquisition materially expands company portfolio and scale; magnitude significant relative to $6.7B market cap but announcement/closing suggests deal was previously disclosed; equity plan assumption is administrative integration.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.